Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: Outcomes of a randomised Phase IIb study

Annals of the Rheumatic Diseases

Volumn 73, Issue 9, 2014, Pages 1607-1615

  Genovese, Mark C ^a   Fleischmann, Roy ^b   Furst, Daniel ^c   Janssen, Namieta ^d   Carter, John ^e   Dasgupta, Bhaskar ^f   Bryson, Judy ^g   Duncan, Benjamin ^g   Zhu, Wei ^g   Pitzalis, Costantino ^h   Durez, Patrick ⁱ   Kretsos, Kosmas ^g  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Houston Institute for Clinical Research   (United States)

^e UNIVERSITY OF SOUTH FLORIDA   (United States)

^f SOUTHEND UNIVERSITY HOSPITAL   (United Kingdom)

^g UCB PHARMA   (Belgium)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOIMMUNE DISEASES; DISEASE ACTIVITY; DMARDS (BIOLOGIC); RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905192115     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204760     Document Type: Article

References (33)

1. Jacobsson LT, Turesson C, Nilsson JA, et al . Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5. (Pubitemid 46707138)
2. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
3. Cohen SB, Cohen MD, Cush JJ, et al. Unresolved issues in identifying and overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheumatol Suppl 2008;81:4-30; quiz 1-4.
4. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci 2009;1173:837-46.
5. Rubbert-Roth A, Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009;11(Suppl 1):S1.
6. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42. (Pubitemid 46834849)
7. Kokebie R, Aggarwal R, Lidder S, et al. The role of synovial fluid markers of catabolism and anabolism in osteoarthritis, rheumatoid arthritis and asymptomatic organ donors. Arthritis Res Ther 2011;13:R50.
8. Sack U, Kinne RW, Marx T, et al. Interleukin-6 in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int 1993;13:45-51. (Pubitemid 23247813)
9. Srirangan S, Choy EH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskelet Dis 2010;2:247-56.
10. Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50.
11. Emery P, Keystone E, Tony HP, et al . IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23.
12. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80.
13. Hashimoto J, Garnero P, van der Heijde D, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. Mod Rheumatol 2011;21:10-15.
14. Hushaw LL, Sawaqed R, Sweis G, et al. Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis. Ther Clin Risk Manag 2010;6:143-52.
15. Nakashima Y, Kondo M, Harada H, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. Mod Rheumatol 2010;20:343-52.
16. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. (Pubitemid 47309731)
17. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol 2009;19:12-19.
18. Genentech Inc. ACTEMRA (tocilizumab) Full Prescribing Information. Revised: 04/2013. http://www.actemra.com/ (accessed 10 Dec 2013).
19. Hickling M, Golor G, Jullion A, et al. Safety and pharmacokinetics of CDP6038, an anti-IL-6 monoclonal antibody, administered by subcutaneous injection and intravenous infusion to healthy male volunteers: a phase 1 study. Ann Rheum Dis 2011;70(Suppl 3):471.
20. Fleischmann R, Kivitz AJ, Wagner F, et al. A Pilot Study Investigating the Tolerability and Pharmacodynamic Effect of Single Intravenous/Subcutaneous Doses of Olokizumab, an Anti-Interleukin-6 Monoclonal Antibody, in Patients with Rheumatoid Arthritis. Ann Rheum Dis 2011;70(Suppl 3):471.
21. Roche. RoACTEMRA (tocilizumab) Summary of Product Characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/ human/000955/WC500054890.pdf (accessed 8 Aug 2013).
22. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
23. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-81.
24. Steinbrocker O, Traeger CH, Batterman RC. Therapeutic criteria in rheumatoid arthritis. JAMA 1949;140:659-62.
25. Araujo J, Zocher M, Wallace K, et al. Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody. J Pharm Biomed Analysis 2011;55:1041-9.
26. Tatarewicz S, Miller JM, Swanson SJ, et al. Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods 2010;357:10-16.
27. Maini RN, Taylor PC, Szechinski J, et al . Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29. (Pubitemid 44497760)
28. Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381:1541-50.
29. Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012;71:1183-9.
30. Hsu B, Sheng S, Weinblatt ME, et al. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-il-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2012;71(Suppl3):61.
31. Genovese MC, Kivitz AJ, Simon Campos JA, et al. Sarilumab for the Treatment of Moderate-to-Severe Rheumatoid Arthritis: Results of a Phase 2, Randomized, Double-Blind, Placebo-Controlled, International Study. ACR/ARHP Annual Scientific Meeting; Chicago. 2011.
32. Finch DK, Sleeman MA, Moisan J, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol 2011;411:791-807.
33. De Bruyn S. Anti-IL-6 Receptor Nanobody (ALX-0061) Seamless "First-in-Human" Phase I/II Proof-of-Concept Study in Patients with Active Rheumatoid Arthritis on Stable Methotrexate Treatment: Single-dose results. Arthritis Rheum 2012;64:S561.